Alan Venook

32PUBLICATIONS
159CO-AUTHORS
PharmacogenomicsMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Feb 03, 2026
Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/<i>DPYD</i>) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing.

Daniel L Hertz, Alan P Venook

|Sep 04, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto

|Sep 03, 2025
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Emily K Bergsland, Susan Geyer, Timothy R Asmis

|Jul 10, 2025
Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing.

Daniel L Hertz, Alan P Venook

|Apr 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database.

Hideaki Bando, Yuriko Takeda, Toshihiro Misumi

|Apr 16, 2025
Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity.

Kai R Trepka, Wesley A Kidder, Than S Kyaw

Pageof 6

Frequent Collaborators

12 joint publications

Heinz-Josef Lenz

11 joint publications

Fang-Shu Ou

8 joint publications

Jeffrey A Meyerhardt

8 joint publications

Eileen O'Reilly